A randomised, double-blind, double-dummy, parallel-group, placebo-controlled, forced dose titration study evaluating the efficacy and safety of GW679769 and paroxetine in subjects with major depressive disorder (MDD).

Trial Profile

A randomised, double-blind, double-dummy, parallel-group, placebo-controlled, forced dose titration study evaluating the efficacy and safety of GW679769 and paroxetine in subjects with major depressive disorder (MDD).

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Casopitant (Primary) ; Paroxetine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 May 2009 Actual patient number changed from 236 to 348 as reported by ClinicalTrials.gov.
    • 29 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top